Why measure both cTnI and cTnT — aren't they redundant?

While both are cardiac-specific troponin isoforms, they provide complementary information in research contexts. cTnI is released exclusively from necrotic cardiomyocytes. cTnT can also be released from viable cardiomyocytes under stress (indicating reversible membrane damage rather than necrosis). The cTnI/cTnT ratio may distinguish necrosis from reversible injury in some research contexts. Certain drug classes preferentially affect one isoform over the other in preclinical models. Combined with FABP3 (1–3 hour early marker) and Myl3 (myofibrillar damage), the four-marker panel provides temporal resolution from early membrane changes through established structural injury.

Why is this panel rat-specific? Are human panels available?

The cardiac and muscle injury panels are validated for rat preclinical models — where serial toxicology sampling during repeat-dose studies provides the most value for drug safety research. For human cardiovascular biomarker research, endothelial and vascular markers (CRP, SAA, ICAM-1, VCAM-1) are available in our Vascular & Angiogenesis panels, and angiogenic factors (VEGF family, Tie-2, PlGF) are covered by Angiogenesis panels. Human-specific cardiac troponin assays may be available via U-PLEX custom configuration — contact us for feasibility assessment based on your specific analytes of interest.

How should I handle hemolyzed samples for troponin measurement?

Hemolysis can occur during preclinical blood collection, particularly with serial sampling from rodents. Unlike colorimetric ELISA where hemoglobin interferes with optical readout, MSD ECL detection is electrically stimulated and unaffected by sample color — hemolyzed samples can still produce valid ECL signal. However, hemolysis indicates red blood cell lysis which may release intracellular contents that affect certain analytes. We recommend: (1) noting hemolysis grade on the sample manifest; (2) processing samples promptly to minimize ex vivo hemolysis; (3) using appropriate needle gauge and collection technique for rodent blood draws. We flag hemolyzed samples during QC review and report hemolysis grade alongside quantitative data.

Home
Platform
MSD Multiplex Assay Services
MSD Cardiovascular Biomarker Panel

MSD V-PLEX

Cardiac Injury · Muscle Injury · Cardiotoxicity

MSD Cardiovascular Biomarker Panel Services

Quantify cardiac troponins (cTnT, cTnI), heart-type fatty acid-binding protein (FABP3), cardiac myosin light chain (Myl3), and skeletal muscle injury markers (CK, TIMP-1) using electrochemiluminescence — multiplex panels for myocardial injury and drug-induced cardiotoxicity research in rat preclinical models.

Drug-induced cardiotoxicity remains a leading cause of drug candidate attrition — from anthracycline cardiomyopathy to kinase inhibitor-induced cardiac dysfunction. Traditional preclinical cardiac safety assessment relies on histopathology and echocardiography, which detect established structural damage. Cardiac troponins provide earlier, quantitative molecular evidence of cardiomyocyte injury — released into circulation within hours of damage. Our cardiovascular panel combines cTnT, cTnI, FABP3, and Myl3 in a single multiplex measurement from 25 µL of plasma, with complementary skeletal muscle injury markers to distinguish cardiac from skeletal muscle toxicity.

Inquire About Cardiovascular Panels View Panel Configurations

Cardiac Biomarkers — Molecular Evidence of Cardiomyocyte Injury

Cardiac troponins are released exclusively from cardiomyocytes — unlike CK-MB or myoglobin, which have skeletal muscle isoforms that reduce specificity. cTnI and cTnT are components of the cardiomyocyte contractile apparatus; their appearance in circulation indicates sarcomere disruption and membrane damage. FABP3 is a small cytoplasmic fatty acid transport protein released earlier than troponins during ischemic events. Myl3 is an essential structural protein released during myofibrillar damage. Together, these four markers provide temporal resolution of cardiac injury: FABP3 rises within 1–3 hours, troponins peak at 12–24 hours, and Myl3 reflects established myofibrillar damage.

Biomarker Profiles
cTnI (cardiac isoform): released upon cardiomyocyte necrosis or reversible membrane damage. The rat panel includes both fast-twitch (skeletal) and cardiac-specific isoforms for tissue-of-origin discrimination.
cTnT: can be released from viable cardiomyocytes under stress as well as from necrotic cells — complementary to cTnI.
FABP3/H-FABP: released within 1–3 hours of ischemic injury — the earliest detectable cardiac biomarker.
Myl3/CMLC1: released during myofibrillar damage — a different dimension of cardiac injury.
CK & TIMP-1 (Skeletal Muscle): standard myocyte damage marker and tissue remodeling indicator.

Panel Configurations

Panel	Plex	Analytes	Application
Rat Cardiac Injury Panel	5	FABP3, cTnT, cTnI (fast-twitch), cTnI (cardiac), Myl3	Cardiotoxicity screening; repeat-dose toxicology
Rat Muscle Injury 2-Plex	2	CK, TIMP-1	Skeletal muscle toxicity screening
Rat Muscle Injury 5-Plex	5	FABP3, cTnT, cTnI (fast-twitch), cTnI (cardiac), Myl3	Combined cardiac + muscle assessment with isoform discrimination

The cTnI fast-twitch isoform identifies skeletal muscle damage, while cTnI cardiac and cTnT are cardiomyocyte-specific — enabling tissue-of-origin discrimination from a single measurement. All services are for research use only.

Research Applications

Drug-Induced Cardiotoxicity

Anthracyclines, HER2 inhibitors, tyrosine kinase inhibitors can cause cardiac injury. Serial troponin monitoring during preclinical repeat-dose toxicology detects cardiomyocyte injury before functional changes on echocardiography.

Ischemia-Reperfusion Studies

FABP3 rises within 1–3 hours — earlier than troponins. Combined with troponins and Myl3, provides temporal resolution of the ischemic injury timeline.

Skeletal Muscle Toxicity

CK is the established myocyte damage marker. Combined with the cardiac panel, skeletal muscle markers enable comprehensive striated muscle safety assessment — distinguishing cardiac-specific from generalized myotoxicity.

Electrochemiluminescence for Cardiac Biomarker Detection

Analytical Advantages

Multiplex isoform discrimination: cardiac-specific cTnI, fast-twitch cTnI, and cTnT measured simultaneously — tissue-of-origin discrimination without separate assays.
Wide dynamic range: troponins span from ~10 pg/mL (baseline) to >10,000 pg/mL (peak injury). ECL's 4–5 log range accommodates this without dilution.
25 µL sample volume: serial sampling in rodent toxicology is plasma-volume-limited. 25 µL per panel supports comprehensive cardiac + muscle safety across multiple timepoints.
Hemolysis-tolerant detection: electrical excitation is unaffected by hemolysis, lipemia, or sample turbidity — common in preclinical plasma samples.

Sample Collection for Cardiac Biomarkers

EDTA plasma required: panels are configured for EDTA plasma collected in preclinical toxicology workflows.
Processing: centrifuge within 30 minutes at 1,500×g for 10 min at 4°C. Transfer to polypropylene cryovials, freeze at −80°C.
Serial sampling: collect pre-dose baseline and multiple timepoints. A single 50–100 µL aliquot supports both cardiac and muscle injury panels.
Stability: troponins are stable for at least 12 months at −80°C. Avoid repeated freeze-thaw cycles — single-use aliquots recommended. Note hemolysis grade on the sample manifest.

Service Details

Service Package

Item	Full Service	Notes
Sample Processing	Included	EDTA plasma processing protocol
Standard Curves	Per-analyte calibrators	Isoform-specific standards
QC Samples	Multi-level, duplicate	Low, medium, high
Data Report	With temporal plots	Cardiac vs. skeletal isoform summary

For Research Use Only. Not for diagnostic procedures.

How to Get Started

Select Panels

Choose cardiac-only or combined cardiac + muscle panels based on expected toxicity profile.

Collect & Ship

EDTA plasma, processed within 30 min at 4°C, frozen at −80°C. Ship on dry ice.

Receive Cardiac Safety Data

Receive quantitative troponin, FABP3, Myl3, and muscle injury data with temporal plots.

Cardiac Biomarker Platforms: MSD vs Clinical Chemistry vs Histopathology

Feature	MSD Cardiac/Muscle Panels	Clinical Chemistry (CK-MB)	Histopathology
Cardiac-Specific Detection	cTnI (cardiac isoform) + cTnT — cardiomyocyte-exclusive	CK-MB — also present in skeletal muscle	Gold standard — direct lesion visualization
Temporal Resolution	Serial — within-animal from 25 µL	Serial — functional but less specific	Terminal only — single endpoint
Muscle vs. Cardiac Discrimination	Cardiac cTnI + fast-twitch sTnI in same well	Cannot distinguish cardiac from skeletal	Can distinguish by tissue
Early Detection	FABP3: 1–3h; cTnI/cTnT: 3–6h	CK-MB: 4–6h	Variable — depends on lesion maturity
Animal Reduction (3Rs)	Yes — within-animal serial sampling	Yes — serial chemistry	No — terminal sacrifice groups

Your Cardiac Safety Data Package

Cardiac safety biomarker report — cTnI (cardiac + fast-twitch), cTnT, FABP3, Myl3, CK, TIMP-1 concentrations with per-analyte QC metrics (Excel + PDF)
Isoform discrimination summary — cardiac-specific vs. skeletal muscle injury assignment based on cTnI isoform differential
Temporal injury kinetics — serial timepoint plots showing injury onset (FABP3), peak (troponins), and recovery
Isoform-specific signal data — multi-plex plate layout and individual analyte standard curves for each panel
Methods documentation — isoform discrimination methodology, strain-specific reference data, and cardiac-specific QC thresholds

Advantages of MSD for Cardiac Safety Assessment

Isoform-resolved cardiac vs. muscle discrimination: cardiac cTnI and fast-twitch sTnI measured simultaneously — unambiguous tissue-of-origin assignment without separate assays.
Translational biomarker continuity: the same cardiac troponins measured clinically are measured in preclinical MSD panels — enabling direct translation of cardiac safety data.
Temporal cascade from 25 µL: FABP3 (1-3h), cTnI/cTnT (3-24h), Myl3 (established damage) — the full sequence captured from one multiplex measurement per timepoint.
Hemolysis-tolerant detection: rodent plasma samples frequently show hemolysis. Electrical excitation is unaffected by sample color.
Within-animal serial sampling: 25 µL per timepoint enables longitudinal cardiac safety monitoring — reducing total animals while increasing statistical power.

Supporting Publications

Herman, E.H. et al. (2011) Toxicologic Pathology. 39(4):653-663. "Baseline serum cardiac troponin I concentrations in Sprague-Dawley, SHR, Wistar, WKY, and Fisher rats." DOI: 10.1177/0192623311406931 · PMID: 21521875
O'Brien, P.J. et al. (2006) Laboratory Animals. 40(2):153-171. "Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals." PMID: 16513236
Reagan, W.J. et al. (2013) Toxicologic Pathology. 41(8):1146-1158. "Comparison of cardiac troponin I and T as indicators of doxorubicin-induced cardiotoxicity." DOI: 10.1177/0192623313482056 · PMID: 23531791
Herman, E.H. et al. (2011) Toxicologic Pathology. 39(7):1091-1106. "A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat." DOI: 10.1177/0192623311419524 · PMID: 21937741

Frequently Asked Questions

Why measure both cTnI and cTnT?

While both are cardiac-specific isoforms, cTnI is released exclusively from necrotic cardiomyocytes, while cTnT can also be released from viable cardiomyocytes under stress. Combined with FABP3 and Myl3, the four-marker panel provides temporal resolution from early membrane changes through established structural injury. For research use only.

Why is this panel rat-specific?

The cardiac and muscle injury panels are configured for rat preclinical models. For human cardiovascular research, endothelial and vascular markers are available in Vascular Injury panel. Human-specific cardiac troponin assays may be available via U-PLEX custom configuration. For research use only.

How should I handle hemolyzed samples?

Unlike colorimetric ELISA, electrochemiluminescence detection is unaffected by sample color. We recommend noting hemolysis grade on the manifest and processing samples promptly. We flag hemolyzed samples during QC review and report hemolysis grade alongside quantitative data. For research use only.

Can I combine cardiac panels with other organ injury panels?

Yes. Liver injury (ARG1 + GST-α, 25 µL), kidney injury (KIM-1 + NGAL, 25 µL), and cardiac panels (cTnI + cTnT + FABP3, 25 µL) all run on the same instrument. A single 75 µL aliquot supports comprehensive multi-organ safety at each timepoint. For research use only.

How does MSD differ from traditional CK-MB measurement?

CK-MB lacks specificity — it constitutes 1-3% of total CK in skeletal muscle, producing false-positive cardiac injury signals during skeletal muscle damage. MSD panels use cardiac-specific cTnI isoform for unambiguous cardiac origin discrimination, with FABP3 detecting injury at 1-3h (before CK-MB) and cTnI/cTnT remaining elevated for 5-10 days. For research use only.

Inquiry Basket